Market Cap 1.46B
Revenue (ttm) 407.32M
Net Income (ttm) -61.60M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -15.12%
Debt to Equity Ratio 1.21
Volume 2,400,500
Avg Vol 3,784,082
Day's Range N/A - N/A
Shares Out 245.25M
Stochastic %K 75%
Beta 0.66
Analysts Strong Sell
Price Target $16.10

Company Profile

Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. Ardelyx, Inc. was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in...

Industry: Biotechnology
Sector: Healthcare
Phone: 510 745 1700
Address:
400 Fifth Avenue, Suite 210, Waltham, United States
LunarApproach
LunarApproach Apr. 5 at 9:09 AM
$ARDX Happy Easter!
0 · Reply
donkeykongreturns
donkeykongreturns Apr. 5 at 7:51 AM
$ARDX True masterclass from a team comprised of genius.
0 · Reply
FerreroRocher
FerreroRocher Apr. 3 at 8:01 PM
$ARDX Is it Monday yet?
1 · Reply
mrbigstakes
mrbigstakes Apr. 3 at 1:57 PM
$ARDX Laura Chico from wed bush is the person Im listening to..Like I did with Dan Ives at Wedbush on PLTR..Laura a world class Biotech Pharma analyst has a $19.00 Base case target..
3 · Reply
Piktoro
Piktoro Apr. 3 at 12:44 PM
$ARDX CMS is making a fuss before the appellate court's decision. I'd love to be wrong, but I don't believe the court will side with the patients and overturn CMS's decision. A VACATE and a complete victory for ARDX would be a fairy tale. However, I anticipate that the court will make an interim decision. REMAND. The agency will need to reconsider its policies. Their assurances that access is currently available are blatantly cynical. I hope that the legislation in Congress will put pressure on CMS's policies. CMS wants to strongly convey that access is available. But this is only on their paper. If the court is competent and non-corrupt, then it should take the right side.
2 · Reply
Cameohitch
Cameohitch Apr. 3 at 7:34 AM
$ARDX CMS even reference their Xphozah guidance in yesterday's newsletter: https://www.cms.gov/training-education/medicare-learning-network/newsletter/mln-connects-newsletter-april-2-2026
8 · Reply
ToadTrader
ToadTrader Apr. 2 at 7:02 PM
$ARDX 360 Day Range of the 24-hr chart, running a Standard Deviation scale, Shows progress in recovering from the latest "Downdraft". Key references are as follows: --- The Range Low on 03/24shows the rebound reaction against the "lower Low, that day. --- The low, this week, Monday reflects a degree of validation toward a shift in trend, to the upside (at least in short term!) The High of today ($6.04) fell short by one penny, to the 200 SMA on this chart with price action maintaining strength, above the $5.83 level (being 1-Std Div, to the low side of Core; the Solid RED Line!). Interestingly, the 50 SMA (solid RED) floating above while the 20 SMA (Lighter Blue) remains below the 200-SMA. With general Market Flow shows some downward slant, the progress of (ARDX) statistically, seems sound, with implications of stability, in course. Progress is slow! Work your Trading Plan to protect your gains and tolerance of Risk! CHEERS!
0 · Reply
5StarTrader
5StarTrader Apr. 2 at 5:08 PM
$ARDX Now that we’ve finished the first quarter, I’m going to wager a little bet that we will see that institutional ownership has increased significantly, while mysteriously the stock price has declined dramatically to this ridiculously low level. I’m also going to bet that when the share price reaches an appropriate market value around $22-$25 pps, it’s going to happen very quickly.
6 · Reply
MedHS55
MedHS55 Apr. 2 at 5:06 PM
$ARDX Trading worse than it should IMO
1 · Reply
EV_Investor
EV_Investor Apr. 2 at 4:54 PM
$ARDX risk on, risk off, risk on, risk off
0 · Reply
Latest News on ARDX
Ardelyx to Participate in Upcoming Investor Conferences

Mar 4, 2026, 8:00 AM EST - 4 weeks ago

Ardelyx to Participate in Upcoming Investor Conferences


Why Ardelyx's Offensive Strategy Doesn't Move The Needle

Feb 21, 2026, 3:25 AM EST - 6 weeks ago

Why Ardelyx's Offensive Strategy Doesn't Move The Needle


Ardelyx Lead Drug Growth Fails To Lift Sentiment, Stock Drops

Feb 20, 2026, 6:50 AM EST - 6 weeks ago

Ardelyx Lead Drug Growth Fails To Lift Sentiment, Stock Drops


Ardelyx, Inc. (ARDX) Q4 2025 Earnings Call Transcript

Feb 20, 2026, 2:44 AM EST - 6 weeks ago

Ardelyx, Inc. (ARDX) Q4 2025 Earnings Call Transcript


Ardelyx Receives New Patent for Tenapanor

Feb 3, 2026, 8:29 AM EST - 2 months ago

Ardelyx Receives New Patent for Tenapanor


Ardelyx: Assessment Of Acquisition Rumors

Jan 21, 2026, 1:04 PM EST - 2 months ago

Ardelyx: Assessment Of Acquisition Rumors


Ardelyx: IBSRELA Momentum Drives Opportunity

Jan 20, 2026, 6:14 AM EST - 2 months ago

Ardelyx: IBSRELA Momentum Drives Opportunity


Ardelyx: Impressive Q3 Record Growth - Why I Buy

Nov 5, 2025, 4:24 AM EST - 5 months ago

Ardelyx: Impressive Q3 Record Growth - Why I Buy


Ardelyx: A Long Overdue Rally

Nov 4, 2025, 3:32 PM EST - 5 months ago

Ardelyx: A Long Overdue Rally


Ardelyx, Inc. (ARDX) Q3 2025 Earnings Call Transcript

Oct 30, 2025, 11:06 PM EDT - 5 months ago

Ardelyx, Inc. (ARDX) Q3 2025 Earnings Call Transcript


Ardelyx: Improved Outlook For Ibsrela And Xphozah

Aug 15, 2025, 6:17 AM EDT - 8 months ago

Ardelyx: Improved Outlook For Ibsrela And Xphozah


Ardelyx, Inc. (ARDX) Q2 2025 Earnings Call Transcript

Aug 4, 2025, 8:11 PM EDT - 8 months ago

Ardelyx, Inc. (ARDX) Q2 2025 Earnings Call Transcript


Ardelyx Announces Changes to the Executive Leadership Team

Aug 4, 2025, 4:08 PM EDT - 8 months ago

Ardelyx Announces Changes to the Executive Leadership Team


Ardelyx, Inc. (ARDX) Q1 2025 Earnings Call Transcript

May 1, 2025, 10:06 PM EDT - 1 year ago

Ardelyx, Inc. (ARDX) Q1 2025 Earnings Call Transcript


LunarApproach
LunarApproach Apr. 5 at 9:09 AM
$ARDX Happy Easter!
0 · Reply
donkeykongreturns
donkeykongreturns Apr. 5 at 7:51 AM
$ARDX True masterclass from a team comprised of genius.
0 · Reply
FerreroRocher
FerreroRocher Apr. 3 at 8:01 PM
$ARDX Is it Monday yet?
1 · Reply
mrbigstakes
mrbigstakes Apr. 3 at 1:57 PM
$ARDX Laura Chico from wed bush is the person Im listening to..Like I did with Dan Ives at Wedbush on PLTR..Laura a world class Biotech Pharma analyst has a $19.00 Base case target..
3 · Reply
Piktoro
Piktoro Apr. 3 at 12:44 PM
$ARDX CMS is making a fuss before the appellate court's decision. I'd love to be wrong, but I don't believe the court will side with the patients and overturn CMS's decision. A VACATE and a complete victory for ARDX would be a fairy tale. However, I anticipate that the court will make an interim decision. REMAND. The agency will need to reconsider its policies. Their assurances that access is currently available are blatantly cynical. I hope that the legislation in Congress will put pressure on CMS's policies. CMS wants to strongly convey that access is available. But this is only on their paper. If the court is competent and non-corrupt, then it should take the right side.
2 · Reply
Cameohitch
Cameohitch Apr. 3 at 7:34 AM
$ARDX CMS even reference their Xphozah guidance in yesterday's newsletter: https://www.cms.gov/training-education/medicare-learning-network/newsletter/mln-connects-newsletter-april-2-2026
8 · Reply
ToadTrader
ToadTrader Apr. 2 at 7:02 PM
$ARDX 360 Day Range of the 24-hr chart, running a Standard Deviation scale, Shows progress in recovering from the latest "Downdraft". Key references are as follows: --- The Range Low on 03/24shows the rebound reaction against the "lower Low, that day. --- The low, this week, Monday reflects a degree of validation toward a shift in trend, to the upside (at least in short term!) The High of today ($6.04) fell short by one penny, to the 200 SMA on this chart with price action maintaining strength, above the $5.83 level (being 1-Std Div, to the low side of Core; the Solid RED Line!). Interestingly, the 50 SMA (solid RED) floating above while the 20 SMA (Lighter Blue) remains below the 200-SMA. With general Market Flow shows some downward slant, the progress of (ARDX) statistically, seems sound, with implications of stability, in course. Progress is slow! Work your Trading Plan to protect your gains and tolerance of Risk! CHEERS!
0 · Reply
5StarTrader
5StarTrader Apr. 2 at 5:08 PM
$ARDX Now that we’ve finished the first quarter, I’m going to wager a little bet that we will see that institutional ownership has increased significantly, while mysteriously the stock price has declined dramatically to this ridiculously low level. I’m also going to bet that when the share price reaches an appropriate market value around $22-$25 pps, it’s going to happen very quickly.
6 · Reply
MedHS55
MedHS55 Apr. 2 at 5:06 PM
$ARDX Trading worse than it should IMO
1 · Reply
EV_Investor
EV_Investor Apr. 2 at 4:54 PM
$ARDX risk on, risk off, risk on, risk off
0 · Reply
Capitulation_0
Capitulation_0 Apr. 2 at 2:36 PM
$ARDX @DrMakaryFDA told reporters today that hastening the IND process is a priority this year. When I asked for some more details, he said one proposal being considered is allowing summary data for IND submission and then raw data before first patient dosed. RDX10531
0 · Reply
Cameohitch
Cameohitch Apr. 2 at 1:51 PM
$ARDX An opinion piece was published on "The Hill" on 03.03.26: "Consider phosphorus control, a central issue for patients with advanced kidney disease. Elevated phosphorus levels contribute to vascular calcification, heart attacks, strokes, and can even render patients ineligible for transplantation. Medications that help manage phosphorus are not optional add-ons; they are essential components of care. Limiting access to them increases medical risk and undermines long-term outcomes." ... "Reforming the bundled payment system for kidney care is an essential step. CMS should recalibrate incentives to support early intervention and evidence-based therapies that slow disease progression. Physicians must have the discretion to treat patients before irreversible decline sets in. " https://thehill.com/opinion/healthcare/5764187-kidney-care-early-intervention/
0 · Reply
Lets_Go_Brndn
Lets_Go_Brndn Apr. 2 at 12:57 PM
$GLSI $ARDX I own both. I would look CLOSELY at Steering Committees. The CEO backgrounds. That’s the difference. At end of 2026 the delta will be exponential with 14 events & FdA Fast-Track. I have 4x+ in GLSI. I don’t need “good luck”.
2 · Reply
ToadTrader
ToadTrader Apr. 2 at 12:35 PM
$ARDX Well, Well.... Looking like I'll be kicking around here a few hours then back to the Lab for further evaluation.... Tests and more tests.... You all take care... Trade safe and try to keep[ this one (ARDX) with an upward attitude! Will likely be able to peak back in later today! CHEERS
0 · Reply
Quantumup
Quantumup Apr. 2 at 12:12 PM
Guggenheim⬇️ $UNCY's PT to $40, reiterated at Buy and said, We had a chance to catch up with the Unicycive management team yesterday after the company released their 4Q 2025 results earlier in the week. $MAZE TVTX SNY TAK $ARDX Here's what else Guggenheim had to say: https://x.com/Quantumup1/status/2039676564908945610?s=20
0 · Reply
Diddysjury
Diddysjury Apr. 2 at 11:54 AM
$ARDX rip
0 · Reply
Cameohitch
Cameohitch Apr. 2 at 10:46 AM
$ARDX "Newer entrants are also beginning to carve out meaningful market share. Ardelyx’s Ibsrela (tenapanor) is a first-in-class, minimally absorbed, oral medication approved to treat IBS-C in adults. It works by inhibiting the sodium/hydrogen exchanger 3 (NHE3) in the gut, reducing sodium absorption and increasing water secretion, resulting in softer stool and reduced abdominal pain." https://xtalks.com/ibs-awareness-month-2026-the-hidden-realities-of-ibs-and-the-ibs-treatment-market-4725/
0 · Reply
Biocontrol
Biocontrol Apr. 2 at 1:01 AM
$ARDX one of the things I like about ardy is I can add at 5.10, 5.60, 6.11, 6.75 and know I’m still gonna crush in two years.
1 · Reply
SilverEagle
SilverEagle Apr. 1 at 9:05 PM
$ARDX revenues starting to ramp. Good looking bio
1 · Reply
Krambo88
Krambo88 Apr. 1 at 7:18 PM
$ARDX April 30th Q1 earnings could be a game changer 💪🏼 or the same old
2 · Reply
Gebinator
Gebinator Apr. 1 at 5:51 PM
$ARDX GOTTA do the DANCE
0 · Reply